Browse our anti-LMO2 (LMO2) Antibodies

Mouse (Murine) LIM Domain Only 2 (Rhombotin-Like 1) (LMO2) interaction partners

1. Genome-wide analysis indicated that LMO2 is required at the hemangioblast stage to position the TAL1 (show TAL1 Antibodies)/LMO2/LDB1 (show LDB1 Antibodies) complex to regulatory elements that are important for the establishment of the hematopoietic developmental program.

2. DNM2 (show DNM2 Antibodies) mutations cooperate with Lmo2 T-cell oncogenes by enhancing IL-7 (show IL7 Antibodies) signalling.

3. Hhex (show HHEX Antibodies) regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.

4. HHEX (show HHEX Antibodies) is a direct transcriptional target of LMO2 consistent with its concordant gene expression.

5. GATA2 (show GATA2 Antibodies) and Lmo2 cooperatively regulate VEGF (show VEGFA Antibodies)-induced angiogenesis and lymphangiogenesis via NRP2 (show NRP2 Antibodies).

6. a regulatory hierarchy of HOX (show MSH2 Antibodies) control of LMO2 in normal development

7. Lyl1 is critical for all oncogenic functions of Lmo2, including upregulation of a stem cell-like gene signature, aberrant self-renewal of thymocytes, and subsequent generation of T-cell leukemia.

8. A model in which the distal control region functions through a chromatin looping mechanism to contact and enhance Lmo2 transcription specifically in erythroid cells.

9. Studied the solution structure of Lmo2(LIM2 (show LHX2 Antibodies)) /Ldb1 (show LDB1 Antibodies)(LID) complex. Results show modular binding of tandem LIM (show PDLIM5 Antibodies) domains in Lmo2 to tandem linear motifs in Ldb1 (show LDB1 Antibodies) is accompanied by several disorder-to-order transitions/ conformational changes in both proteins.

10. Studies demonstrate that Etv2 (show ETV2 Antibodies) is expressed during and required for yolk sac (show ADCY10 Antibodies) hematoendothelial development, and that Lmo2 is one of the downstream targets of Etv2 (show ETV2 Antibodies).

Human LIM Domain Only 2 (Rhombotin-Like 1) (LMO2) interaction partners

1. LMO2 has a predominantly cytoplasmic location in breast cancer cells. LMO2 interaction with cofilin1 regulates actin cytoskeleton dynamics, promoting tumor cell invasion and metastasis.

2. These data indicate that Lhx2 (show LHX2 Antibodies) is capable of blocking proliferation of T-ALL-derived cells by both LMO2-dependent and -independent means. We propose Lhx2 (show LHX2 Antibodies) as a new molecular tool for anti-T-ALL drug development.

3. stromal LMO2 may be responsible for zonal characteristic of Prostate cancer

4. The transcriptional factor LMO2 regulates endothelial proliferation and angiogenesis in vitro.

5. This article demonstrates a novel and unexpected function of the LMO2 oncogenic transcription factor in controlling DNA replication that we unravelled via an unbiased proteome-wide screen for LMO2-interacting partners.

6. Findings suggest that LMO2 loss may be a good predictor for the presence of MYC (show MYC Antibodies) translocation in large B-cell lymphoma.

7. FOXP3 (show FOXP3 Antibodies) binds LMO2 in vitro, resulting in decreased interaction between LMO2 and TAL1 (show TAL1 Antibodies), providing a molecular mechanism for FOXP3 (show FOXP3 Antibodies)-mediated transcriptional modulation in T-ALL.

8. recurrent activating intronic mutations of LMO2, a prominent oncogene (show RAB1A Antibodies) in T-cell acute lymphoblastic leukemia (T-ALL). Heterozygous mutations were identified in PF-382 and DU.528 T-ALL cell lines in addition to 3.7% of pediatric (6 of 160) and 5.5% of adult (9 of 163) T-ALL patient samples.

9. Data indicate a novel functional mechanism of LMO2 in facilitating the delivery of actin monomers to the branched microfilament and increasing lamellipodia/filopodia formation in basal-type breast cancer cells.

10. we demonstrate previously unrecognized mechanisms by which LMO2 alters human T-cell development in vivo; these mechanisms correlate with human T-ALL leukemogenesis.

Zebrafish LIM Domain Only 2 (Rhombotin-Like 1) (LMO2) interaction partners

1. The transcriptional factor LMO2 regulates endothelial proliferation and angiogenesis in vitro. Furthermore, LMO2 is required for angiogenesis and tissue healing in vivo. Thus, LMO2 is a critical determinant of vascular and tissue regeneration.

2. a loss-of-function mutation in lmo2, a gene specifically required for hematopoiesis and vascular development, results in failure of optic fissure closure

3. in the absence of inducers of erythroid or myeloid haematopoiesis, Scl/Tal1 (show TAL1 Antibodies)-Lmo2-induced haemangioblasts differentiate into endothelial cells

4. Transcriptional regulation of lmo2 promoter during hematopoietic and vascular development in zebrafish is elucidated.

5. Scl (show TAL1 Antibodies)/Lmo2 complex does not appear to autoregulate, as neither gene's expression is affected by depletion of the other